NEW YORK, March 30 (Reuters) - The U.S. withdrawal of Novartis AG's Zelnorm treatment for irritable bowel syndrome highlights the sometimes narrow dividing line between success and failure in the ...
ZURICH, March 30 (Reuters) - Novartis AG has pulled its bowel drug Zelnorm from the U.S. market at the request of regulators, after clinical trial data indicated a link to heart attacks and stroke.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results